10 March 2023 | News
To increase ability to support APAC-based clients with a local presence
Image credit: shutterstock
Crown Bioscience, a global contract research organisation (CRO) and JSR Life Sciences company, has announced the opening of a new site in Singapore to expand the company’s capacity to support both global and local biotech and pharma companies engaged in preclinical and translational oncology drug discovery and development.
The new facility will initially offer a broad portfolio of high-demand cell line-derived xenograft (CDX) and syngeneic models, alongside supporting analytical biomarker capabilities including flow cytometry and pathology services.
The company is also collaborating with the established biomedical community in Singapore to bring not only the foundational capabilities of Crown Bioscience’s preclinical services to Singapore but also novel technologies and services.
To support the growth goals for the Singapore site, and with a particular focus on the burgeoning local biotech industry, Crown Bioscience has entered into a distribution agreement with Biosys Corporation, a specialised commercial partner with unique contacts within the Singaporean life sciences ecosystem.
The investment in Singapore reflects a broader strategy to increase Crown Bioscience’s ability to support Asia Pacific (APAC)-based clients with a local presence. In 2022 the company announced a joint venture launch with sister company MBL in Japan, alongside facility expansions and upgrades to the company’s Chinese presence.